Evolus, Inc. EOLS
Institutional shares held
49 Million
57.2K
calls
5.5K
puts
Total value of holdings
$589M
$686K
calls
$66K
puts
Market Cap
$674M
56,094,800
Shares Out.
Institutional ownership
87.4%
# of Institutions
173
We take great care to ensure that the data presented and summarized in this overview for Evolus, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EOLS
View all-
Perceptive Advisors LLC New York, NY5.15MShares$61.8 Million1.9% of portfolio
-
Tang Capital Management LLC San Diego, CA5MShares$60 Million4.14% of portfolio
-
Black Rock Inc. New York, NY4.01MShares$48.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.17MShares$38.1 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.13MShares$37.6 Million1.74% of portfolio
-
State Street Corp Boston, MA1.42MShares$17.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.37MShares$16.4 Million0.01% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.29MShares$15.5 Million0.43% of portfolio
-
Stonepine Capital Management, LLC Bend, OR1.26MShares$15.2 Million11.27% of portfolio
-
Geode Capital Management, LLC Boston, MA1.21MShares$14.6 Million0.0% of portfolio
Latest Institutional Activity in EOLS
Top Purchases
Top Sells
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Insider Transactions at EOLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
6,251
-1.21%
|
$75,012
$12.4 P/Share
|
|
Mar 18
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
103,376
-16.72%
|
$1,343,888
$13.26 P/Share
|
|
Mar 18
2025
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
4,536
-4.53%
|
$58,968
$13.26 P/Share
|
|
Mar 18
2025
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,996
-4.93%
|
$116,948
$13.26 P/Share
|
|
Mar 18
2025
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
27,904
-7.15%
|
$362,752
$13.26 P/Share
|
|
Mar 12
2025
|
Karah Herdman Parschauer Director |
SELL
Open market or private sale
|
Direct |
12,888
-28.59%
|
$154,656
$12.99 P/Share
|
|
Mar 07
2025
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,663
+16.34%
|
-
|
|
Mar 07
2025
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,832
+15.11%
|
-
|
|
Mar 07
2025
|
Karah Herdman Parschauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+14.04%
|
-
|
|
Mar 07
2025
|
Vikram Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+2.82%
|
-
|
|
Mar 07
2025
|
Albert G White Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+19.51%
|
-
|
|
Mar 07
2025
|
Brady Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+11.16%
|
-
|
|
Mar 07
2025
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+15.12%
|
-
|
|
Mar 07
2025
|
Simone Blank Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+8.72%
|
-
|
|
Mar 07
2025
|
Rui Avelar Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,776
+5.74%
|
-
|
|
Mar 07
2025
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
95,399
+13.37%
|
-
|
|
Dec 23
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
10,502
-1.97%
|
$105,020
$10.85 P/Share
|
|
Dec 23
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,586
-1.07%
|
$15,860
$10.85 P/Share
|
|
Dec 23
2024
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
2,252
-0.61%
|
$22,520
$10.85 P/Share
|
|
Sep 06
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,276
-2.16%
|
$45,864
$14.98 P/Share
|
Last 12 Months Summary
Buy / Acquisition
571K
Shares
From
11
Insiders
| Grant, award, or other acquisition | 240K shares |
|---|---|
| Exercise of conversion of derivative security | 331K shares |
Sell / Disposition
726K
Shares
From
7
Insiders
| Open market or private sale | 726K shares |
|---|